A large peer-reviewed study using health data from Denmark, Norway, and Sweden suggests that people who take GLP-1 receptor agonists — the drug class that includes Ozempic and Wegovy — may have a lower risk of developing Parkinson's disease compared to people taking a different diabetes medication. The findings add to growing scientific interest in the broader neurological effects of these widely used drugs.
What the Study Found
Researchers conducted a cohort study drawing on nationwide health registers across three Scandinavian countries. The study included 158,961 new users of GLP-1 receptor agonists and 188,065 new users of sulfonylureas — a standard class of diabetes medication used as an active comparator — all aged 45 years or older.
The study used an active-comparator, new-user design, a rigorous methodological approach that compares two groups of patients who are both starting a medication for the first time. This helps reduce the kind of bias that can appear when comparing drug users to non-users. Among GLP-1 users in the study, liraglutide accounted for 72.9% of GLP-1 receptor agonist use. Liraglutide is the active ingredient in Victoza and Saxenda.
Why This Matters for GLP-1 Patients
GLP-1 receptor agonists work by mimicking a natural gut hormone to regulate blood sugar, slow digestion, and reduce appetite. Scientists have increasingly suspected these drugs may also have protective effects on the brain, partly because GLP-1 receptors are present in the central nervous system.
Parkinson's disease is a progressive neurological condition with no known cure, making prevention research especially important. If GLP-1 drugs genuinely reduce the risk of developing Parkinson's, that could become a meaningful secondary benefit for the millions of people already taking these medications for diabetes or weight management — though it would not, on its own, be a reason to start taking them.
Key takeaway: This large Scandinavian study of nearly 350,000 people found a potential link between GLP-1 receptor agonist use and lower Parkinson's disease risk — but the research is observational, meaning it cannot yet prove that the drugs directly cause this protective effect.
Important Limitations to Keep in Mind
Observational cohort studies, even large and well-designed ones, can demonstrate associations but cannot definitively prove cause and effect. Factors like overall health, lifestyle, or access to care could still influence the results, even with the active-comparator design. Additionally, because liraglutide made up the majority of GLP-1 use in this dataset, it is not yet clear whether this potential protective effect applies equally to newer agents like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). Dedicated clinical trials would be needed to confirm any causal relationship.
What to Watch Next
This study is part of a broader wave of research examining what GLP-1 drugs might do beyond blood sugar and weight control. Scientists are actively investigating potential links to reduced risks of heart disease, addiction, kidney disease, and now neurological conditions like Parkinson's. Expect more clinical trial data in the coming years as researchers work to determine whether these associations are real, consistent, and drug-specific.
Frequently Asked Questions
These findings are an encouraging signal, but they are not a reason to change your medication regimen on your own. Always speak with your prescribing doctor or pharmacist before making any decisions about your treatment — they can help you weigh the latest research in the context of your personal health history and goals.
- Peer-reviewed journal article, 'Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study,' Diabetes, Obesity and Metabolism, date not specified in source material.